David  Baltimore net worth and biography

David Baltimore Biography and Net Worth

David Baltimore, Ph.D. has served on our board of directors since our conversion to a corporation in January 2009, and prior to that was a director of Regulus Therapeutics LLC since November 2007. Dr. Baltimore is currently President Emeritus and Distinguished Professor of Biology at the California Institute of Technology (“Caltech”), and before that from 1997 to 2006, Dr. Baltimore served as president of the California Institute of Technology. From 1968 to 1972, Dr. Baltimore served as an associate professor at the Massachusetts Institute of Technology, and from 1972 to 1997 was a professor at the Massachusetts Institute of Technology. From 1990 to 1994, Dr. Baltimore served as professor at The Rockefeller University where he also served as the president from July 1990 to December 1991. Dr. Baltimore served as a director of Amgen Inc., a publicly held biotechnology company from 1997 to May 2018, and also served as a director of Immune Design Corp., a publicly held biotechnology company, from 1997 until its acquisition by Merck & Co., Inc. in February 2019. In 1975, Dr. Baltimore received the Nobel Prize in Medicine as a co-recipient. Dr. Baltimore holds a Ph.D. in biology from The Rockefeller University and a B.A. from Swarthmore College.

What is David Baltimore's net worth?

The estimated net worth of David Baltimore is at least $180.90 thousand as of January 30th, 2025. Dr. Baltimore owns 22,169 shares of Regulus Therapeutics stock worth more than $180,899 as of December 5th. This net worth estimate does not reflect any other investments that Dr. Baltimore may own. Learn More about David Baltimore's net worth.

How do I contact David Baltimore?

The corporate mailing address for Dr. Baltimore and other Regulus Therapeutics executives is 10628 SCIENCE CENTER DRIVE SUITE 225, SAN DIEGO CA, 92121. Regulus Therapeutics can also be reached via phone at (858) 202-6300 and via email at [email protected]. Learn More on David Baltimore's contact information.

Has David Baltimore been buying or selling shares of Regulus Therapeutics?

David Baltimore has not been actively trading shares of Regulus Therapeutics during the past quarter. Most recently, on Thursday, January 30th, David Baltimore bought 19,610 shares of Regulus Therapeutics stock. The stock was acquired at an average cost of $1.06 per share, with a total value of $20,786.60. Following the completion of the transaction, the director now directly owns 22,169 shares of the company's stock, valued at $23,499.14. Learn More on David Baltimore's trading history.

Who are Regulus Therapeutics' active insiders?

Regulus Therapeutics' insider roster includes Christopher Aker (VP), David Baltimore (Director), Crispina Calsada (CFO), Kathryn Collier (Director), Denis Drygin (Insider), Joseph Hagan (CEO), and Preston Klassen (Insider). Learn More on Regulus Therapeutics' active insiders.

Are insiders buying or selling shares of Regulus Therapeutics?

During the last twelve months, Regulus Therapeutics insiders bought shares 3 times. They purchased a total of 81,610 shares worth more than $171,166.60. During the last twelve months, insiders at the biopharmaceutical company sold shares 4 times. They sold a total of 223,998 shares worth more than $282,237.48. The most recent insider tranaction occured on June, 3rd when insider Preston Klassen bought 12,000 shares worth more than $95,880.00. Insiders at Regulus Therapeutics own 4.4% of the company. Learn More about insider trades at Regulus Therapeutics.

Information on this page was last updated on 6/3/2025.

David Baltimore Insider Trading History at Regulus Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/30/2025Buy19,610$1.06$20,786.6022,169View SEC Filing Icon  
See Full Table

David Baltimore Buying and Selling Activity at Regulus Therapeutics

This chart shows David Baltimore's buying and selling at Regulus Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Regulus Therapeutics Company Overview

Regulus Therapeutics logo
Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $8.16
Low: $8.16
High: $8.16

50 Day Range

MA: $8.10
Low: $7.87
High: $8.30

2 Week Range

Now: $8.16
Low: $0.83
High: $8.35

Volume

N/A

Average Volume

1,018,158 shs

Market Capitalization

$564.92 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.35